VolitionRx Limited (NYSE:VNRX) Forecasted to Post FY2024 Earnings of ($0.35) Per Share

VolitionRx Limited (NYSE:VNRX - Free Report) - Investment analysts at Zacks Small Cap issued their FY2024 earnings estimates for VolitionRx in a note issued to investors on Monday, April 8th. Zacks Small Cap analyst S. Ralston forecasts that the company will post earnings of ($0.35) per share for the year. The consensus estimate for VolitionRx's current full-year earnings is ($0.44) per share.

VolitionRx (NYSE:VNRX - Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million.

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $2.50 target price on shares of VolitionRx in a research note on Wednesday, March 27th.

VolitionRx Trading Down 1.2 %

Shares of VNRX traded down $0.01 on Wednesday, reaching $0.72. 80,481 shares of the company's stock were exchanged, compared to its average volume of 178,969. The stock has a market capitalization of $59.26 million, a P/E ratio of -1.42 and a beta of 1.35. The business has a 50 day moving average price of $0.94 and a two-hundred day moving average price of $0.84. VolitionRx has a 12 month low of $0.55 and a 12 month high of $2.10.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in shares of VolitionRx Limited (NYSE:VNRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 147,038 shares of the company's stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent quarter. Institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.